Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

كيوتو، اليابان--(BUSINESS WIRE)--بدأت شركة .Murata Manufacturing Co., Ltd (المدرجة في بورصة طوكيو تحت الرمز:6981) (الرقم التعريفي الدولي للأوراق المالية: JP3914400001) الإنتاج التجاري لسلسلة LLD، وهي أصغر مكثفات سيراميكية متعددة الطبقات (MLCC) ثلاثية الأطراف منخفضة الحث المكافئ (ESL) في العالم*. بأبعاد تبلغ 0201 بوصة فقط (0.6 × 0.3 مم)، تعمل المنتجات الجديدة على تقليص مساحة التركيب بنسبة 64% تقريباً مقارنةً بأصغر منتج سابق من Murata بمقاس 0402 بوصة (1.0 × 0.5 مم)، مما يوفر مساحة قيمة لوحة الدوائ...

SWORDS, Ireland--(BUSINESS WIRE)--Trane Technologies (NYSE: TT), a global climate innovator, today announced the successful laboratory demonstration of the industry’s first 800-volt direct current (800 VDC) cooling architecture designed to support the mission-critical energy and thermal demands of next-generation AI factories and gigawatt-scale data centers. First validated on a high-efficiency chiller platform, the proof-of-concept demonstrates the performance, efficiency and design advantages...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

CANTON, Mass.--(BUSINESS WIRE)--This week at the MEDITECH LIVE leadership summit, healthcare organizations using MEDITECH's Traverse Exchange interoperability network highlighted significant benefits gained since implementing the network’s new Consolidated Patient Summary. Unveiled at last year's summit, the enhanced workflow has seen swift adoption among clinicians, providing care teams with faster access to critical patient information, reducing duplicate testing, and supporting more informed...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

DURHAM, N.C.--(BUSINESS WIRE)--HemoSonics LLC announced today that it will be honored during Premier’s annual Supplier Innovation Celebration at its 2026 Breakthroughs Conference and Exhibition. The Innovation Celebration recognizes groundbreaking healthcare technologies launched throughout the year and highlights how these products help improve the health of communities. “Premier’s recognition of the Quantra Systems clearance in Obstetrics reinforces our commitment to delivering rapid, actiona...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date. “This agreement reflects the next stage of responsible NAD+ science,” said Rob Fried,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a tru...